E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor

Molecular Therapy

Volumn 5, Issue 5, 2002, Pages 627-634

  Takahashi, Minoru ^a   Sato, Tsutomu ^a   Sagawa, Tamotsu ^a   Lu, Yue ^a   Sato, Yasushi ^a   Iyama, Satoshi ^a   Yamada, Yasuyuki ^a   Fukaura, Junki ^a   Takahashi, Sho ^a   Miyanishi, Koji ^a   Yamashita, Toshiharu ^a   Sasaki, Katsunori ^a   Kogawa, Katsuhisa ^a   Hamada, Hirofumi ^a   Kato, Junji ^a   Niitsu, Yoshiro ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gene therapy; Hepatocellular carcinoma; Highly tumor specific; Replication competent adenovirus; fetoprotein

Indexed keywords

ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; ONYX 015; VIRUS PROTEIN;

5' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; CYTOMEGALOVIRUS; CYTOTOXICITY; DNA FLANKING REGION; DRUG POTENCY; DRUG SPECIFICITY; ENHANCER REGION; FEASIBILITY STUDY; FEMALE; GENE CONSTRUCT; GENE DELETION; GENE EXPRESSION; GENE SILENCING; GENE THERAPY; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PLAQUE FORMING CELL; PROMOTER REGION; PROTEIN SECRETION; TUMOR CELL; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA; CYTOMEGALOVIRUS;

EID: 0036112191     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2002.0589     Document Type: Article

References (55)

1. Trends in primary liver cancer
2. Rising incidence of hepatocellular carcinoma in the United States
3. Therapy of unresectable hepatocellular carcinoma
4. Progress toward human gene therapy
5. Liver-directed gene therapy: Prospects and problems
6. Immunological gene therapy with ex vivo gene-modified tumor cells: A critique and a reappraisal
7. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12
8. Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma
9. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma
10. Gene therapy for α-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene
11. Mechanisms of cell death induced by suicide genes encoding purine nucleoside phosphorylase and thymidine kinase in human hepatocellular carcinoma cells in vitro
12. Gene therapy: A molecular approach to cancer treatment
13. Regulated expression of artificial chimeric genes contained in retroviral vectors: Implications for virus-directed enzyme prodrug therapy (VDEPT) and other gene therapy applications
14. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human (-fetoprotein gene promoter
15. Utilization of variant-type of human (-fetoprotein promoter in gene therapy targeting for hepatocellular carcinoma
16. A novel strategy of cell targeting based on tissue-specific expression of the ecotropic retrovirus receptor gene
17. Retrovirus-mediated gene therapy for hepatocellular carcinoma: Selective and enhanced suicide gene expression regulated by human α-fetoprotein enhancer directly linked to its promoter
18. In vivo gene therapy for α-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene
19. HVJ-liposome-mediated transfection of HSVtk gene driven by AFP promoter inhibits hepatic tumor growth of hepatocellular carcinoma in SCID mice
20. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma
21. A position-dependent silencer plays a major role in repressing α-fetoprotein expression in human hepatoma
22. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection
23. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
24. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
25. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
26. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication
27. Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy
28. Mutational analysis of the adenovirus E1a gene: The role of transcriptional regulation in transformation
29. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status
30. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
31. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A
32. Replication-selective oncolytic adenoviruses: Virotherapy aimed at genetic targets in cancer
33. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication
34. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours
35. Evaluation of HSV-tk gene therapy in a rat model of chemically induced hepatocellular carcinoma by intratumoral and intrahepatic artery routes
36. Adenovirus E1A under the control of heterologous promoters: Wide variation in E1A expression levels has little effect on virus replication
37. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
38. Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy
39. Packaging capacity and stability of human adenovirus type 5 vectors
40. Adenovirus type 5 early region 1b gene product is required for efficient shutoff of host protein synthesis
41. Long-term correction of bilirubin-UDP-glucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period
42. Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long-term gene therapy in Gunn rats
43. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination
44. Immune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity
45. Circumventing the immune response to adenovirus-mediated gene therapy
46. Targeting adenovirus
47. Integrin-mediated transfection with peptides containing arginine-glycine-aspartic acid domains
48. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins
49. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells
50. Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide
51. Cell-specific enhancer activity in a far upstream region of the human α-fetoprotein gene
52. Adenovirus E1A coding sequences that enable ras and pmt oncogenes to transform cultured primary cells
53. Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents
54. Induction of transformation and p53-dependent apoptosis by adenovirus type 5 E4orf6/7 cDNA
55. An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration